Recent News

• 03.30.2026 - Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
• 03.27.2026 - Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
• 03.25.2026 - Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
• 03.25.2026 - Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
• 03.18.2026 - Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study
• 03.18.2026 - Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients

Recent Filings

• 03.27.2026 - D Notice of Exempt Offering of Securities
• 03.27.2026 - D Notice of Exempt Offering of Securities
• 03.27.2026 - RW Registration Withdrawal Request
• 03.27.2026 - D Notice of Exempt Offering of Securities
• 03.26.2026 - EX-99.1 EX-99.1
• 03.26.2026 - 8-K Current report
• 03.25.2026 - EFFECT Notice of Effectiveness
• 03.24.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 03.24.2026 - S-1/A General form for registration of securities under the Securities Act of 1933
• 03.23.2026 - S-1/A General form for registration of securities under the Securities Act of 1933